Research: Scientific Publications

Scientific Publications

2012

• IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice.
  Fu-Gang Zhu, Dong Yu, Ekambar R. Kandimalla, Nicola La Monica, and Sudhir Agrawal. Presented at the American Association of Immunologists (AAI) on May 5, 2012
• IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in mouse models of psoriasis.
  Weiwen Jiang, Fu-Gang Zhu, Dong Yu, Ekambar R. Kandimalla, Nicola La Monica and Sudhir Agrawal. Poster presentation at the American Association of Immunologists (AAI) on May 6, 2012

2011

• Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
  Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. Clin Cancer Res. 2011 Oct 15;17(20):6531-41.
• Synthesis, purification, and characterization of immune-modulatory oligodeoxynucleotides that act as agonists of Toll-like receptor 9.
  Putta MR, Yu D, Kandimalla ER. Methods Mol Biol. 2011;764:263-77.
• Synthesis, purification, and characterization of oligoribonucleotides that act as agonists of TLR7 and/or TLR8.
  Lan T, Kandimalla ER. Methods Mol Biol. 2011;764:249-61.
• Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
  Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR. Cell Immunol. 2011;270(2):126-34.
• Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity.
  Bhagat L, Putta MR, Wang D, Yu D, Lan T, Jiang W, Sun Z, Wang H, Tang JX, La Monica N, Kandimalla ER, Agrawal S. J Med Chem. 2011 Apr 28;54(8):3027-36.
• PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
  Hensley HH, Hannoun-Levi JM, Hachem P, Mu Z, Stoyanova R, Khor LY, Agrawal S, Pollack A. Int J Cancer. 2011 Feb 15;128(4):962-73.

2010

• Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8
  Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER, Agrawal S.
  Mol Cancer Ther. 2010 Jun;9(6):1788-97. Epub 2010 Jun 1.
• Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
  Putta MR, Yu D, Bhagat L, Wang D, Zhu FG, Kandimalla ER.
  J Med Chem. 2010 May 13;53(9):3730-8.
• A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.
  Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L.
  Vaccine. 2010 Apr 30;28(20):3522-30. Epub 2010 Mar 21.
• Synthesis and immunological activities of novel agonists of toll-like receptor 9.
  Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR.
  Cell Immunol. 2010;263(1):105-13. Epub 2010 Mar 10.
• Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.
  Dharmapuri S, Peruzzi D, Mennuni C, Calvaruso F, Giampaoli S, Barbato G, Kandimalla ER, Agrawal S, Scarselli E, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L.
  Mol Ther. 2009 Oct;17(10):1804-13. Epub 2009 Jul 21.Erratum in: Mol Ther. 2010 Feb;18(2):447.
• Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity
  Putta MR, Zhu FG, Wang D, Bhagat L, Dai M, Kandimalla ER, Agrawal S.
  Bioconjug Chem. 2010 Jan;21(1):39-45.
• Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
  Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S.
  J Med Chem. 2009 Nov 12;52(21):6871-9.
• Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.
  Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S.
  J Med Chem. 2009 Aug 27;52(16):5108-14.
• Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8
  Lan T, Putta MR, Wang D, Dai M, Yu D, Kandimalla ER, Agrawal S.
  Biochem Biophys Res Commun. 2009; 386:443-448.
• Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8
  Lan T, Bhagat L, Wang D, Dai M, Kandimalla ER, Agrawal S.
  Bioorg Med Chem Lett. 2009; 19:2044-2047.
• Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9
  Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N.
  Clin Cancer Res. 2009; 15:1575-1584.
• Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9
  Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S.
  J Med Chem. 2009; 52:551-558.
• Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction
  Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S.
  Antimicrob Agents Chemother. 2008; 52:4320-4325.
• Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive and androgen-insensitive prostate cancer cells to radiation
  Udayakumar TS, Hachem P, Ahmed MM, Agrawal S, Pollack A.
  Mol Cancer Res. 2008; 6:1742-1754. Erratum in: Mol Cancer Res. 2008; 6:1957.
• Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro
  Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, Kandimalla ER, Yu D, Zurbriggen A, Doherr MG, Peel J, Roosje PJ.
  Vet Immunol Immunopathol. 2008;124:120-131.
• Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo
  Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon AL, Agrawal S, Pollack A.
  Prostate. 2008; 68:599-609.
• Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
  Stoyanova R, Hachem P, Hensley H, Khor LY, Mu Z, Hammond ME, Agrawal S, Pollack A.
  Int J Radiat Oncol Biol Phys. 2007; 68:1151-1160.
• Synthetic agonists of Toll-like receptors 7, 8 and 9
  Agrawal S, Kandimalla ER.
  Biochemical Society Transactions (2007) Volume 35, part 6.
• Agonists of Toll-like Receptor 9 Containing Synthetic Dinucleotide Motifs
  Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S.
  J Med Chem. 2007 Dec 13;50(25):6411-8.
• Stablized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8
  Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu FG, Tang JX, Putta MR, Cong YP, Trombino AF, Sullivan T,
  Agrawal S.
  Proc Natl Acad Sci USA (2007) 104, 13750-13755.
• Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced Eustachian tube dysfunction in rats
  Blanks DA, Ebert CS Jr, Eapen RP, Zdanski C, Kandimalla ER, Agrawal S, Prazma J.
  Otolaryngol Head Neck Surg. (2007) 137 321-326.
  
• Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats
  Ebert CS Jr, Rose AS, Blanks DA, Eapen RP, Kandimalla ER, Agrawal S, Prazma J, Pillsbury HC 3rd.
  Otolaryngol Head Neck Surg. (2007) 137, 250-255.
  
• TLR9 agonist acts by different mechanisms synergizing with bevacizumad in sensitive and cetuximab-resistant colon cancer xenografts
  Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini, G, DePlacido S, Kandimalla ER, Agrawal S, Ciardiello F, Torotora G.
  Proc Natl Acad Sci USA (2007) 104, 12468-12473.
  
• Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice
  Zhu FG, Kandimalla ER, Yu D, Agrawal S
  J Allergy Clin Immunol. (2007) 120, 631-637.
  
• Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications
  Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S.
  Nucleic Acids Res. (2006) 34, 3231-3238.
  
  

For publications prior to 2006, please contact info@iderapharma.com